[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-337330-105":3,"detail-sidebar-cat-0-en-105":85,"doc-detail-337330-en":134},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":78,"head_meta":80,"extra_data":82,"updated_unix":84},105,"en","survival-outcomes-of-radium-223-therapy-for-metastatic-castration-resistant-prostate-cancer-following-national-health-insurance-reimbursement-in-taiwan","Survival outcomes of radium-223 therapy for metastatic castration-resistant prostate cancer following national health insurance reimbursement in Taiwan","","Radium-223 dichloride (Ra-223) prolongs overall survival in metastatic castration-resistant prostate cancer (mCRPC) with symptomatic bone metastases, yet individual outcomes vary substantially. This study evaluates prognostic determinants of patient survival after Taiwan National Health Insurance reimbursement for Ra-223 therapy. A retrospective cohort of mCRPC patients treated at Taipei Veterans General Hospital received Ra-223 intravenously at 55 kBq/kg every 4 weeks.",{"@graph":14,"@context":77},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/survival-outcomes-of-radium-223-therapy-for-metastatic-castration-resistant-prostate-cancer-following-national-health-insurance-reimbursement-in-taiwan/337330/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/survival-outcomes-of-radium-223-therapy-for-metastatic-castration-resistant-prostate-cancer-following-national-health-insurance-reimbursement-in-taiwan/337330.png","ImageObject",300,407,{"name":42,"@type":43},"Ophelia","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-01","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69,73],{"name":60,"@type":61,"acceptedAnswer":62},"What was the primary goal of the study on Ra-223 therapy in Taiwan?","Question",{"text":63,"@type":64},"To evaluate prognostic determinants associated with patient survival after National Health Insurance reimbursement for Ra-223 therapy in metastatic castration-resistant prostate cancer.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was Ra-223 administered in the study?",{"text":68,"@type":64},"Each intravenous Ra-223 dose was administered at 55 kBq/kg at 4-week intervals, based on the patients’ treatment records.",{"name":70,"@type":61,"acceptedAnswer":71},"Which baseline factors were significantly associated with survival?",{"text":72,"@type":64},"Survival was significantly associated with ≤5 bone metastases, baseline PSA ≤36 ng/mL, baseline alkaline phosphatase \u003C115 U/L, and baseline hemoglobin >12 g/dL.",{"name":74,"@type":61,"acceptedAnswer":75},"Did National Health Insurance reimbursement change overall survival compared with self-pay?",{"text":76,"@type":64},"No significant difference in overall survival was observed between patients who received NHI reimbursement and those who self-paid.","https://schema.org",{"og:url":32,"og:type":79,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":81,"canonical":32},"index,follow",{"doc_id":83,"site_id":7},337330,1790211120,{"code":4,"msg":86,"data":87},"success",[88,92,96,100,105,110,115,119,123,126,130],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Exam",70,"exam",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},5,"Comic",60,"comic",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},6,"Technology",50,"technology",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},7,"Healthcare",40,"healthcare",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":117,"slug":118},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":121,"slug":122},"Religion & Spirituality",20,"religion-spirituality",{"id":121,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":121,"slug":125},"World Cup","world-cup",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":127,"slug":129},10,"Lifestyle","lifestyle",{"id":131,"doc_module":4,"doc_module_name":25,"category_name":132,"show_sort_weight":101,"slug":133},19,"General","general",{"code":4,"msg":86,"data":135},{"doc_id":83,"user_id":136,"nickname":42,"user_avatar":137,"doc_module":4,"category_id":116,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":111,"language":143,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":144,"faqs":145,"seo_title":146,"seo_description":12,"update_tm":147,"read_time":148,"preview_page_count":33,"preview_urls":149},7971461741311,"https://ap-avatar.wpscdn.com/avatar/74000253aff267980c6?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779345379180704826","J Chin MedAssoc  \nOriginal article  \nSurvival outcomes of radium-223 therapy for metastatic castration-resistant prostate cancer following national health insurance reimbursement in Taiwan  \nShan-Fan Yaoa, William J. Huangb, Tzu-Chun Weic, Yuh-Feng Wanga, Ko-Han Lina, Lien-Hsin Hua,c, Chien-Hsin Tinga, Tse-Hao Leea, Skye Hsin-Hsien Yehd, Nan-Jing Penga,c,*  \naDepartment of Nuclear Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, ROC; bDepartment of Urology, Taipei Veterans General Hospital, Taipei, Taiwan, ROC; cSchool of Medicine, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC; dSchool of Medicine, National Defense Medical Center, Taipei, Taiwan, ROC  \nAbstract  \nBackground: Radium-223 dichloride (Ra-223) prolongs overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) with symptomatic bone metastases. However, there is considerable variation in outcomes among individuals. We aimed to evaluate the prognostic determinants associated with patient survival following National Health Insurance (NHI) reimbursement for Ra-223 therapy in Taiwan.  \nMethods: Patients with mCRPC who underwent Ra-223 treatment at Taipei Veterans General Hospital were retrospectively enrolled. Each intravenous Ra-223 dose was administered at 55 kBq/kg at 4-week intervals. Clinical outcomes were obtained from medical records; potential prognostic factors for survival were assessed. Kaplan-Meier analysis was used to generate cumulative survival curves; between-group differences were evaluated using the Chi-squared test. Statistical significance was set at p \u003C 0.05. Results: Seventy-six patients underwent Ra-223 therapy; 62 patients received NHI reimbursement and the remainder self-paid. Fifty patients (65 .8%) completed six cycles of treatment; 26 (34 .2%) received 1 to 5 cycles. Mortality occurred in 47 patients. Factors significantly associated with survival included ≤five bone metastases (p = 0.0018), baseline prostate-specific antigen (PSA)≤36 ng/mL (p = 0.0004), baseline alkaline phosphate (ALP) \u003C115 U/L (p = 0.0007), and baseline hemoglobin (Hb) >12 g/dL (p = 0.0029) . Patients who completed six cycles of treatment achieved significantly higher OS compared to those who did not (p \u003C 0.0001) . There has been a 4.4-fold increase in the number of patients since reimbursement began; there was no significant difference in OS between patients who received NHI reimbursement and those who self-paid.  \nConclusion: Administration of Ra-223 demonstrates considerable potential to extend the survival of patients with mCRPC. Survival outcomes may be influenced by various prognostic factors. However, no significant difference in OS was observed subsequent to reimbursement of Ra-223 therapy for mCRPC through the NHI system in Taiwan.  \nKeywords: Metastatic castration-resistant prostate cancer; Prostate-specific antigen; Radium-223  \n1. INTRODUCTION  \nProstate cancer is a common malignancy that afflicts males. The incidence of this disease escalates with age, with the majority of  \n*Address correspondence. Dr. Nan-Jing Peng, Department of Nuclear Medicine, Taipei Veterans General Hospital, 201, Section 1, Shi-Pai Road, Taipei112, Taiwan, [ROC. E-mail address: njpeng@vghtpe.gov.tw](ROC. E-mail address: njpeng@vghtpe.gov.tw) (N.-J. Peng).  \nAuthor contributions: Dr. Nan-Jing Peng and Dr. Skye Hsin-Hsien Yeh contributed equally to this work.  \nConflicts of interest: Dr. William J. Huang, an editorial board member at Journal of the Chinese Medical Association, had no role in the peer review process of or decision to publish this article. The other authors declare that they have no conflicts of interest related to the subject matter or materials discussed in this article.  \nJournal of Chinese Medical Association. (2024) 87: 734-740.  \nReceived October 5, 2023; accepted March 6, 2024. doi: 10. 1097/JCMA.0000000000001111  \nCopyright © 2024, the Chinese Medical Association. This is an open access article u","cbCaipKxyID84c9D","https://ap.wps.com/l/cbCaipKxyID84c9D","pdf",891521,"English","# Introduction\n## Background and rationale\n# Methods\n## Study design and treatment regimen\n# Results\n## Treatment cycles and survival predictors\n## Reimbursement vs self-pay outcomes\n# Conclusion","[{\"question\":\"What was the primary goal of the study on Ra-223 therapy in Taiwan?\",\"answer\":\"To evaluate prognostic determinants associated with patient survival after National Health Insurance reimbursement for Ra-223 therapy in metastatic castration-resistant prostate cancer.\"},{\"question\":\"How was Ra-223 administered in the study?\",\"answer\":\"Each intravenous Ra-223 dose was administered at 55 kBq/kg at 4-week intervals, based on the patients’ treatment records.\"},{\"question\":\"Which baseline factors were significantly associated with survival?\",\"answer\":\"Survival was significantly associated with ≤5 bone metastases, baseline PSA ≤36 ng/mL, baseline alkaline phosphatase \\u003c115 U/L, and baseline hemoglobin \\u003e12 g/dL.\"},{\"question\":\"Did National Health Insurance reimbursement change overall survival compared with self-pay?\",\"answer\":\"No significant difference in overall survival was observed between patients who received NHI reimbursement and those who self-paid.\"}]","Survival outcomes of radium-223 therapy for metastatic castration-resistant prostate cancer following national health insurance reimbursement in Taiwan | PDF",1790018613,18,[150,154,158,162],{"page_no":22,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0feb3fab4354787a8a89220953f33ece.webp",983,1310,{"page_no":26,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dc21a039d76cc5a709b42c081ff6a73b.webp",982,1309,{"page_no":30,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/24ec12865e635bdaf200604e3dc87c38.webp",981,1308,{"page_no":33,"url":163,"width":164,"height":165},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6b1633bfb3ffc65134ccd29af5ff2a6d.webp",980,1306]